Browsing by Author "Manisha Sahay"

Now showing 1 - 16 of 16

Clinicopathological Features and Outcomes of Fibrillary Glomerulonephritis in an Indian Cohort: A Multicentric Study
(Elsevier Inc., 2025) Priti Meena; Anila Abraham Kurien; Raja P. Ramachandran; Mahesha Vankalakunti; Vinant Bhargava; Manisha Sahay; Vishwanath Siddini; Pallav S. Gupta; Atanu Pal; Prit Pal Singh; Gayatri Pegu; Gireesh G. Reddy; P. S. Priyamvada; Sai Sameera; Pinaki Mukhopadhyay; Vinay Rathore; Saurabh Nayak; Shivendra P. Singh; Arun Prabhahar; Ganesh Srinivasa Prasad; Nitin Kumar; Mangalee Edwin Fernando; Sharon Kandari; Dinesh Kumar Thanikachalam; Manjunath Doshetty; Jyotish Chalil Gopinath; Bipin C. Munjappa; Sree Bhushan Raju; Sandip Kumar Panda
[No abstract available]
Indian chronic kidney disease study: Design and methods
(Blackwell Publishing, 2017) Vivek Kumar; Ashok Kumar Yadav; Sishir Gang; Oommen John; Gopesh K. Modi; Jai Prakash Ojha; Rajendra Pandey; Sreejith Parameswaran; Narayan Prasad; Manisha Sahay; Santosh Varughese; Seema Baid-Agarwal; Vivekanand Jha
Aim: The rate and factors that influence progression of chronic kidney disease (CKD) in developing countries like India are unknown. A pan-country prospective, observational cohort study is needed to address these knowledge gaps. Methods: The Indian Chronic Kidney Disease (ICKD) study will be a cohort study of approximately 5000 patients with mild to moderate CKD presenting to centres that represent different geographical regions in India. Time to 50% decline in baseline estimated glomerular filtration rate, need of renal replacement therapy or any new cardiovascular disease (CVD) event or death from CVD are the primary end points. Value of Study: This study will provide the opportunity to determine risk factors for CKD progression and development of CVD in Indian subjects and perform international comparisons to determine ethnic and geographical differences. A bio-repository will provide a chance to discover biomarkers and explore genetic risk factors. © 2016 Asian Pacific Society of Nephrology
ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19
(Wolters Kluwer Medknow Publications, 2021) Vivek Kute; Sandeep Guleria; Anil Bhalla; Ashish Sharma; Sanjay Agarwal; Manisha Sahay; Santosh Varughese; Narayan Prasad; Prem Varma; Sunil Shroff; Harsh Vardhan; Manish Balwani; Shruti Dave; Dhamendra Bhadauria; Manish Rathi; Dhananjai Agrawal; Pankaj Shah; Jai Prakash
[No abstract available]
ISOT consensus statement for the kidney transplant recipient and living donor with a previous diagnosis of COVID-19
(Wolters Kluwer Medknow Publications, 2022) Vivek Kute; Sandeep Guleria; Anil Bhalla; Ashish Sharma; S. Agarwal; Manisha Sahay; Santosh Varughese; Narayan Prasad; P. Varma; Sunil Shroff; Harsh Vardhan; Manish Balwani; Shruti Dave; Dhamendra Bhadauria; Manish Rathi; Dhananjay Agarwal; Pankaj Shah; Jai Prakash
[No abstract available]
National Consensus Statement on Role of Bisoprolol across Cardiovascular Continuum: Special Focus on Women
(Journal of Association of Physicians of India, 2025) Hriday Kumar Chopra; Kamal Kumar Sethi; Tiny Nair; Chandrashekhar Kashinath Ponde; Saumitra Ray; Sarita Rao; Shanmunga Sundaram; Dinesh K. Khullar; Navin C. Nanda; Jatinder Pal Singh Sawhney; Sarita M. Bajaj; Yatin Mehta; Arvind Kumar Pancholia; Pradeep Jain; Ashok Kumar Omar; Aditya K. Kapoor; Rishi Rishi Sethi; Atul Damodar Abhyankar; Vinod Kumar Sharma; Anil Dhall; Ajay Kumar Sinha; Shishu Shankar Mishra; Satya Narayan Rautray; Gyarsi Lal Sharma; Ashwani Mehta; Rajeev Agarwala; Rajeev Kumar Rajput; Ajay Umakant Mahajan; Sanjay C. Porwal; Ramesh K. Hotchandani; Vishal Rastogi; Rajeev Passey; Mohan Bhargava; Justin Paul Gnanaraj; Dorairaj Prabhakaran; Vivudh Pratap Singh; Vinod Mittal; Vitull Kumar Gupta; Anil Kumar Bhalla; Virender Kumar Katyal; Ishwarappa Balekundri Vijaylakshami; Asha Moorthy; Poonam Malhotra; Vanita Arora; Mona Bhatia; Prabhavathy Bhat; Shibba Takkar Chhabra; Sugandhi Gopal; Tripti Deb; Preeti Gupta; Hemlata Tewari; Anupam Goel; Rekha Mishra; Lovelina Singh; Zakia Khan; Geeta S. Sheth; Chandra Mukhi; Inder Pal Singh Kalra; Yogender Kumar Arora; Uttara Das; Kavita Tyagi; Satya Nand Pathak; Samir Kubba; Saurabh Bagga; Asha Mahilmaran; Ameet Sattur; Rohit Tandon; Dharmender Jain; Hetan C. Shah; Cecily Mary Majella; Ravi Prakash; Manish Aggarwal; Ruchi Verma; Sumit Sethi; Alka Gujral; Kanika Sood; Sonia Rawat; Varsha Kaul; Surinder S. Arora; Manjiti Arora; Veena Bhat; Anil Kumar Bali; Sanjay Sood; Shakuntala Dawesar; Bhushan K. Dawesar; Nilakshi Deka; Makarand Paithankar; Rajiv Handa; Nitish Parmar; Sheikh U. Nabi; Naveen K. Garg; Sandeep Sharma; Vivek Tandon; Manoj Pabrai; Samshad Alam; Manju Tyagi; Manisha Sahay; Manju Hotchandani; Anupama Kathpalia; Ish Kathpalia
Cardiovascular diseases (CVDs) represent a significant health concern worldwide, with women facing distinct challenges in the prevention, diagnosis, and management of these conditions. In India, hypertension is a prevalent cardiovascular (CV) risk factor, affecting nearly one-third of adults, and women experience a disproportionately high burden across all age-groups. The CV continuum, which spans from risk factors to CV events and ultimately to heart failure (HF), demonstrates how the progression of CVD impacts women at each stage differently due to gender-specific mechanisms like hormonal influences, pregnancy complications and the effects of menopause. This manuscript aims to present a set of consensus statements developed by an expert panel in India, focusing on the role of bisoprolol across the CV continuum with special attention to women. The consensus was formed based on a thorough review of clinical experiences, existing clinical data and alignment with both global and regional clinical guidelines. The manuscript highlights the gender-specific CV risks faced by women, their higher mortality rates following acute cardiac events, delayed diagnoses and less aggressive treatments. It also discusses bisoprolol as an effective therapy for managing hypertension, HF and other CV conditions in women. Bisoprolol's benefits include consistent blood pressure (BP) control, improved outcomes in HF and reduced CV risks, particularly in postmenopausal women and those with comorbidities. The manuscript underscores the need for gender-tailored approaches to the CV continuum, from prevention through to management, to address these challenges and improve outcomes for women. © The Author(s).
Nonmedical factors and health-related quality of life in CKD in India
(American Society of Nephrology, 2020) Gopesh K. Modi; Ashok K. Yadav; Arpita Ghosh; Kajal Kamboj; Prabhjot Kaur; Vivek Kumar; Shobhit Bhansali; Narayan Prasad; Manisha Sahay; Sreejith Parameswaran; Santosh Varughese; Sishir Gang; Shivendra Singh; Dipankar Sircar; Natarajan Gopalakrishnan; Ajay Jaryal; Sanjay Vikrant; Seema Baid Agarwal; Vivekanand Jha
Background and objectives Patient-reported outcomes have gained prominence in the management of chronic noncommunicable diseases. Measurement of health-related quality of life is being increasingly incorporated into medical decision making and health care delivery processes. Design, setting, participants, & measurements The Indian Chronic Kidney Disease Study is a prospective cohort of participants with mild to moderate CKD. Baseline health-related quality of life scores, determined by the standardized Kidney Disease Quality of Life 36 item instrument, are presented for the inception cohort (n52919). Scores are presented on five subscales: mental component summary, physical component summary, burden, effect of kidney disease, and symptom and problems; each is scored 0–100. The associations of socioeconomic and clinical parameters with the five subscale scores and lower quality of life (defined as subscale score <1 SD of the sample mean) were examined. The main socioeconomic factors studied were sex, education, occupation, and income. The key medical factors studied were age, eGFR, diabetes, hypertension, and albuminuria. Results The mean (SD) subscale scores were physical component summary score, 4369; mental component summary score, 48610; burden, 61633; effects, 87613; and symptoms, 90620. Among the socioeconomic variables, women, lower education, and lower income were negatively associated with reduced scores across all subscales. For instance, the respective b-coefficients (SD) for association with the physical component summary subscale were 22.6 (23.4 to 21.8), 21.5 (22.2 to 20.7), and 21.6 (22.7 to 20.5). Medical factors had inconsistent or no association with subscale scores. The quality of life scores also displayed regional variations. Conclusions In this first of its kind analysis from India, predominantly socioeconomic factors were associated with quality of life scores in patients with CKD. © 2020 by the American Society of Nephrology.
Notto covid-19 vaccine guidelines for transplant recipients
(Wolters Kluwer Medknow Publications, 2021) Vivek Kute; Sanjay Agarwal; Jai Prakash; Sandeep Guleria; Sunil Shroff; Ashish Sharma; Prem Varma; Narayan Prasad; Manisha Sahay; Subhash Gupta; S. Sudhindran; Kewal Krishan; Vasanthi Ramesh; Sunil Kumar
In December 2019, novel coronavirus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within a few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID-19 vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID-19 infection or at least diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno-compromised patients should not receive live vaccines as they can cause vaccine-related disease and hence the guidelines suggest that all transplant recipients should receive age-appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population. © 2021 Indian Journal of Nephrology.
NOTTO COVID-19 vaccine guidelines for transplant recipients
(Wolters Kluwer Medknow Publications, 2021) Vivek Kute; Sanjay K. Agarwal; Jai Prakash; Sandeep Guleria; Sunil Shroff; Ashish Sharma; Prem Varma; Narayan Prasad; Manisha Sahay; Subhash Gupta; S. Sudhindran; Kewal Krishan; Vasanthi Ramesh; Sunil Kumar
In December 2019 Novel corona virus (SARS-CoV-2) infection started in Wuhan and resulted in a pandemic within few weeks' time. Organ transplant recipients being at a risk for more severe COVID-19 if they get SARS CoV-2 viral infection, COVID 19 Vaccine has a significant role in these patients. The vaccine is a safer way to help build protection and would either prevent COVID -19 infection or atleast diminish the severity of the disease. It would also reduce the risk of the continuing transmission and enhance herd immunity. Immuno compromised patients should not receive live vaccines as they can cause vaccine related disease and hence the guidelines suggest that all transplant recipients should receive age appropriate 'inactivated vaccine' as recommended for general population. Though trials have not been undertaken on transplant recipients, efficacy and safety of COVID-19 vaccine have been scientifically documented for few vaccines among the general population. © 2021 Indian Journal of Transplantation | Published by Wolters Kluwer - Medknow.
NOTTO transplant specific guidelines with reference to COVID-19
(Wolters Kluwer Medknow Publications, 2020) Vivek Kute; Sandeep Guleria; Jai Prakash; Sunil Shroff; Narayan Prasad; Sanjay Agarwal; Santosh Varughese; Subhash Gupta; A. Gokhale; Manisha Sahay; Ashish Sharma; Prem Varma; Anil Bhalla; Harsh Vardhan; Manish Balwani; Shruti Dave; Dhamendra Bhadauria; Manish Rathi; Dhananjay Agarwal; Pankaj Shah; Vasanthi R; Rajiv Garg
[No abstract available]
NOTTO transplant specific guidelines with reference to COVID-19
(Wolters Kluwer Medknow Publications, 2020) Vivek Kute; Sandeep Guleria; Jai Prakash; Sunil Shroff; Narayan Prasad; Sanjay Agarwal; Santosh Varughese; Subhash Gupta; A. K Gokhale; Manisha Sahay; Ashish Sharma; Prem Varma; Anil Bhalla; Harsh Vardhan; Manish Balwani; Shruti Dave; Dhamendra Bhadauria; Manish Rathi; Dhananjay Agarwal; Pankaj Shah; Vasanthi Ramesh; Rajiv Garg
[No abstract available]
Outcomes of symptomatic coronavirus disease 19 in maintenance hemodialysis patient in India
(John Wiley and Sons Inc, 2021) Narayan Prasad; Manas Ranjan Behera; Mansi Bhatt; Sanjay Kumar Agarwal; N. Gopalakrishnan; Edwin Fernando; Arpita Roy Chaudhary; Manisha Sahay; Shivendra Singh; Apoorva Jain; Shruti Tapiawala; Aniket Kamble; Umesh Khanna; Rubina Bohra; Anurag Gupta; Urmila Anandh; Vivekanand Jha
Background: Maintenance hemodialysis (MHD) patients face disadvantages with higher risk of acquiring SARS-CoV-2 infection, atypical manifestations, and associated multiple comorbidities. We describe patients' outcomes with symptomatic COVID-19 on MHD in a large cohort of patients from India. Methods: Data were collected prospectively from hemodialysis units in 11 public and private hospitals between March 15, 2020, and July 31, 2020. The survival determinants were analyzed using stepwise backward elimination cox-regression analysis. Results: Of the 263 total patients (mean age 51.76 ± 13.63 years and males 173) on MHD with symptomatic COVID-19, 35 (13.3%) died. Those who died were older (p = 0.01), had higher frequency of diabetic kidney disease (p = 0.001), comorbidities (p = 0.04), and severe COVID-19 (p = 0.001). Mortality was higher among patients on twice-weekly MHD than thrice-weekly (p = 0.001) and dialysis through central venous catheter (CVC) as compared to arteriovenous fistula (p = 0.001). On multivariate analysis, CVC use (HR 2.53, 95% CI 1.26–5.07, p = 0.009), disease severity (HR = 3.54, 95% CI 1.52–8.26, p = 0.003), and noninvasive ventilatory support (HR 0.59, 95% CI 0.25–0.99, p = 0.049) had significant effect on mortality. Conclusion: The adjusted mortality risk of COVID-19 in MHD patients is high in patients associated with severe COVID-19 and patients having CVC as vascular access. © 2021 Wiley Periodicals LLC.
Prescription Practices in Patients With Mild to Moderate CKD in India
(Elsevier Inc., 2021) Narayan Prasad; Ashok Kumar Yadav; Monica Kundu; Jasmin Sethi; Ajay Jaryal; Dipankar Sircar; Gopesh K. Modi; Kajal Kamboj; Manisha Sahay; Natarajan Gopalakrishnan; Prabhjot Kaur; Sanjay Vikrant; Santosh Varughese; Seema Baid-Agrawal; Shivendra Singh; Sishir Gang; Sreejith Parameswaran; Vivek Kumar; Arpita Ghosh; Vivekanand Jha
Introduction: Patients with chronic kidney disease (CKD) require multiple medications. There is no information on prescription patterns or the use of evidence-based therapies for management of CKD from low-middle-income countries. Using baseline data from the Indian CKD (ICKD) cohort, we describe the drug prescription practices in patients with mild to moderate CKD. Methods: The ICKD study is a prospective, observational cohort study of mild to moderate kidney disease across 11 centers in India. We analyzed all the prescriptions captured at enrollment in the ICKD study. Drugs were categorized into 11 different groups. We provide descriptive data on prescription details and evaluate the appropriateness of medication use. Results: Complete prescription data were available in 3966 out of 4056 (97.8%) subjects enrolled in the ICKD database. Most patients had stage 3 CKD, 24.9% had diabetic kidney disease, 87% had hypertension, and 25.5% had moderate to severe proteinuria. Renin-angiotensin-aldosterone system blockers were prescribed in less than half (47.9%) and in 58.8% of patients with proteinuric CKD. Metformin was prescribed in 25.7% of diabetic subjects with CKD. Only 40.4% of patients were taking statins; 31.1% and 2.8% subjects with anemia were receiving iron and erythropoiesis-stimulating agents, respectively. Conclusion: This study highlights the missed opportunities for improving outcomes through appropriate prescriptions of drugs in patients with CKD. There is need for dissemination of evidence-based guidelines and institution of sustainable implementation practices for improving the overall health of patients with CKD. © 2021 International Society of Nephrology
Protocol and Methods: Role of Levothyroxine on the Progression of Chronic Kidney Disease in Subclinical Hypothyroid Populations (LP‑CKD) – A Multicenter Randomized Controlled Trial
(Wolters Kluwer Medknow Publications, 2023) Narayan Prasad; Shivendra Singh; Vivek Kumar; Manisha Sahay; Arpita Ray Chaudhury; Manas Ranjan Behera; Ravi Shankar Kushwaha; Deependra Yadav; Sonam Gautam; Akhilesh Jaiswal
Introduction: Subclinical hypothyroidism (SCH) is highly prevalent and associated with chronic kidney disease (CKD). However, it is still unanswered whether the restoration of euthyroid status in these patients will be beneficial in retarding a decline in glomerular filtration rate in early CKD patients. We aim to evaluate the efficacy of levothyroxine therapy versus placebo in slowing estimated glomerular filtration rate (eGFR) decline among CKD patients (stage 2–4) with SCH. Methods: This study will be a multicentric, double‑blind, randomized, parallel‑group, placebo‑controlled study. A total of 500 CKD patients, 250 patients in the treatment group and 250 patients in the placebo group, will be randomized. The randomization between the treatment arm and placebo arm will be performed as per the computer‑generated random number table in a 1:1 ratio. The sample size was calculated based on the assumed reduction in eGFR after 1‑year follow‑up in the treatment and placebo groups of 10% and 25%, respectively, at a minimum two‑sided 99% confidence interval and 90% power of the study and considering 20% loss on follow‑up. Each patient will be followed every 3 months for at least 1 year after randomization. Individuals completing 1‑year follow‑up visits will be considered for analysis. The baseline and follow‑up data will be compared between the treatment and placebo groups. The study will evaluate the efficacy and safety of levothyroxine therapy versus placebo in slowing eGFR decline among CKD patients (stage 2‑4) with SCH. The primary endpoint will be the end of follow‑up of the patients, reduction of eGFR by ≥50% from a baseline of that patient, or development of ESKD or death of the patients. The secondary endpoint will be any cardiovascular event or arrhythmia after the institution of the drug. © 2023 Wolters Kluwer Medknow Publications. All rights reserved.
Renin-angiotensin blocker use is associated with improved cardiovascular mortality in Indian patients with mild-moderate chronic kidney disease—findings from the ICKD study
(Frontiers Media S.A., 2022) Narayan Prasad; Ashok Kumar Yadav; Monica Kundu; Ajay Jaryal; Dipankar Sircar; Gopesh Modi; Manisha Sahay; Natarajan Gopalakrishnan; Sanjay Vikrant; Santosh Varughese; Seema Baid-Agrawal; Shivendra Singh; Sishir Gang; Sreejith Parameswaran; Arpita Ghosh; Vivek Kumar; Vivekanand Jha
Introduction: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are the antihypertensive drug class of choice in patients with chronic kidney disease (CKD). Head-to-head comparisons of the renal or non-renal outcomes between ACEI/ARB users and nonusers have not been conducted in all population groups. We examined the renal and cardiovascular outcomes in users and nonusers enrolled in the Indian Chronic Kidney Disease (ICKD) Study. Methods: A total of 4,056 patients with mild-moderate CKD were studied. Patients were categorized as ACEI/ARB users or nonusers. Major adverse kidney events [ESKD (end stage kidney disease), ≥50% decline in eGFR and kidney death], all-cause mortality, and cardiovascular mortality were analyzed over a median follow-up period of 2.64 (1.40, 3.89) years between the two groups. Results: Out of a total of 4,056 patients, 3,487 (87%) were hypertensive. The adjusted sub-hazard ratio (SHR) and 95 % CI for ACEI /ARB users was 0.85 (0.71, 1.02) for MAKE, 0.80 (0.64, 0.99) for a 50% decline in eGFR, and 0.72 (0.58, 0.90) for ESKD. For cardiovascular mortality, ACEI/ARB users were at lower risk (SHR = 0.55, 95% CI: 0.34, 0.88). Diuretic users were at increased risk of all-cause mortality (HR = 1.95, 95% CI: 1.50, 2.53) and cardiovascular mortality (adjusted SHR = 1.73, 95% CI: 1.09, 2.73). There was non-significant association between the use of other antihypertensives and any of the end points. Discussion: ACEI/ARB use is associated with slower rate of decline in eGFR in those with CKD stage 1-3. ACEI/ARB users had a significantly lower risk of renal outcomes, and cardiovascular mortality. Copyright © 2022 Prasad, Yadav, Kundu, Jaryal, Sircar, Modi, Sahay, Gopalakrishnan, Vikrant, Varughese, Baid-Agrawal, Singh, Gang, Parameswaran, Ghosh, Kumar and Jha.
The Adverse Effect of COVID Pandemic on the Care of Patients With Kidney Diseases in India
(Elsevier Inc, 2020) Narayan Prasad; Mansi Bhatt; Sanjay K. Agarwal; H.S. Kohli; N. Gopalakrishnan; Edwin Fernando; Manisha Sahay; Mohan Rajapurkar; Arpita Roy Chowdhary; Manish Rathi; Tarun Jeloka; Valentine Lobo; Shivendra Singh; A.K. Bhalla; Umesh Khanna; S.B. Bansal; P.K. Rai; Amol Bhawane; Urmila Anandh; Ajit Kumar Singh; Bharat Shah; Amit Gupta; Vivekanand Jha
Introduction: The coronavirus disease 2019 (COVID-19) pandemic has affected the care of patients with noncommunicable diseases, including those suffering from kidney-related ailments. Many parts of the world, including India, adopted lockdown to curb community transmission of disease. The lockdown affected transportation, access to health care facilities, and availability of medicines and consumables as well as outpatient and inpatient services. We aimed to analyze the effect of lockdown imposed due to the COVID-19 pandemic on the care of patients with kidney diseases in India. Methods: We surveyed 19 major hospitals (8 in the public and 11 in the private sector) to determine the effect of lockdown on the care of patients with kidney disease, including those on dialysis after the first 3 weeks of lockdown. Results: The total number of dialysis patients in these centers came down from 2517 to 2404. Approximately 710 (28.2%) patients missed 1 or more dialysis sessions, 69 (2.74%) required emergency dialysis sessions, 104 (4.13%) stopped reporting for dialysis, and 9 (0.36%) were confirmed to have died. Outpatient attendance in the surveyed hospital came down by 92.3%, and inpatient service reduced by 61%. Tele-consultation was started but was accessed by only a small number of patients. Conclusion: Lack of preparedness before lockdown resulted in an interruption in health care services and posed an immediate adverse effect on the outcome of dialysis patients and patients with kidney disease in India. The long-term impact on the health of patients with less severe forms of kidney disease remains unknown. © 2020 International Society of Nephrology
The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics
(Oxford University Press, 2022) Vivek Kumar; Ashok Kumar Yadav; Jasmine Sethi; Arpita Ghosh; Manisha Sahay; Narayan Prasad; Santosh Varughese; Sreejith Parameswaran; Natarajan Gopalakrishnan; Prabhjot Kaur; Gopesh K. Modi; Kajal Kamboj; Monica Kundu; Vivek Sood; Neeraj Inamdar; Ajay Jaryal; Sanjay Vikrant; Saurabh Nayak; Shivendra Singh; Sishir Gang; Seema Baid-Agrawal; Vivekanand Jha
Background: Chronic kidney disease (CKD) is an important cause of morbidity and mortality worldwide. There is a lack of information on epidemiology and progression of CKD in low-middle income countries. The Indian Chronic Kidney Disease (ICKD) study aims to identify factors that associate with CKD progression, and development of kidney failure and cardiovascular disease (CVD) in Indian patients with CKD. Methods: ICKD study is prospective, multicentric cohort study enrolling patients with estimated glomerular filtration rate (eGFR) 15-60 mL/min/1.73 m2, or >60 mL/min/1.73 m2 with proteinuria. Clinical details and biological samples are collected at annual visits. We analysed the baseline characteristics including socio-demographic details, risk factors, disease characteristics and laboratory measurements. In addition, we compared characteristics between urban and rural participants. Results: A total of 4056 patients have been enrolled up to 31 March 2020. The mean ± SD age was 50.3 ± 11.8 years, 67.2% were males, two-thirds of patients lived in rural areas and the median eGFR was 40 mL/min/1.73 m2. About 87% were hypertensive, 37% had diabetes, 22% had CVD, 6.7% had past history of acute kidney injury and 23% reported prior use of alternative drugs. Diabetic kidney disease, chronic interstitial nephritis (CIN) and CKD-cause unknown (CKDu) were the leading causes. Rural participants had more occupational exposure and tobacco use but lower educational status and income. CIN and unknown categories were leading causes in rural participants. Conclusions: The ICKD study is the only large cohort study of patients with mild-to-moderate CKD in a lower middle income country. Baseline characteristics of study population reveal differences as compared with other cohorts from high-income countries. © 2021 The Author(s) 2021.